A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 92,364 shares of SRRK stock, worth $763,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,364
Holding current value
$763,850
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$7.84 - $16.79 $724,133 - $1.55 Million
92,364 New
92,364 $769,000
Q3 2023

Nov 14, 2023

SELL
$6.02 - $7.76 $229,963 - $296,432
-38,200 Reduced 41.12%
54,700 $388,000
Q2 2023

Aug 11, 2023

SELL
$5.79 - $9.11 $275,025 - $432,725
-47,500 Reduced 33.83%
92,900 $700,000
Q1 2023

May 12, 2023

SELL
$7.36 - $12.72 $44,160 - $76,320
-6,000 Reduced 4.1%
140,400 $1.12 Million
Q4 2022

Feb 13, 2023

BUY
$7.02 - $9.76 $484,379 - $673,440
69,000 Added 89.15%
146,400 $1.33 Million
Q3 2022

Nov 14, 2022

BUY
$5.33 - $11.3 $135,915 - $288,150
25,500 Added 49.13%
77,400 $536,000
Q2 2022

Aug 12, 2022

BUY
$4.66 - $13.96 $241,854 - $724,524
51,900 New
51,900 $285,000
Q3 2021

Nov 12, 2021

SELL
$27.38 - $42.21 $1.62 Million - $2.49 Million
-59,000 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$26.34 - $46.62 $229,158 - $405,594
-8,700 Reduced 12.85%
59,000 $1.71 Million
Q1 2021

May 13, 2021

SELL
$45.96 - $68.02 $41,364 - $61,218
-900 Reduced 1.31%
67,700 $3.43 Million
Q4 2020

Feb 10, 2021

SELL
$13.72 - $51.57 $16,464 - $61,884
-1,200 Reduced 1.72%
68,600 $3.33 Million
Q3 2020

Nov 13, 2020

SELL
$10.54 - $18.47 $10,540 - $18,470
-1,000 Reduced 1.41%
69,800 $1.24 Million
Q2 2020

Aug 13, 2020

BUY
$10.37 - $20.64 $734,196 - $1.46 Million
70,800 New
70,800 $1.29 Million

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $427M
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.